AudioCodes (Nasdaq:AUDC), a leading provider of Voice over IP (VoIP) technologies and Voice Network products, reported the launch of the Software Enterprise Session Border Controller (E-SBC), a software-only member of its E-SBC product family.
The Software E-SBC has already been selected for OEM by a leading unified communications vendor.
CRWE, Crown Equity Holdings Inc., CRWE.OB
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWE?s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
CRWE?s division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.
Content published on the World Wide Web is immediately available to a global audience of users. This makes the World Wide Web a very cost-effective medium to publish information. Reaching more than 190 countries.
It is relatively inexpensive to publish information on the Internet. At a fraction of the cost to publish information by traditional methods, various organizations and individuals can now distribute information to millions of users.
More about CRWE at www.crownequityholdings.com.
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported positive new results from the 52-56 month follow-up study of patients who participated in the company's U.S. Study NX02-0016 of NX-1207 for the treatment of BPH (benign prostatic hyperplasia or enlarged prostate) completed in 2007.
The results of the follow-up study provided evidence confirming the durable benefits from NX-1207 treatment for BPH. Two blinded placebo-controlled Phase III studies of NX-1207 2.5 mg for the treatment of BPH as well as a third open label safety study are currently underway in the U.S. and nearing full enrollment.
The company and its European partner, Recordati, recently announced the start of a Phase III clinical trial in Europe for NX-1207 for BPH.
Illumina, Inc. (NASDAQ:ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, issued the following statement regarding Roche?s decision to extend for the second time its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:
"Illumina?s Board of Directors continues to believe that Roche's offer is grossly inadequate, and that Illumina is positioned to create far more value than Roche has offered. Our stockholders clearly agree."
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. stockblizzard.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://stockblizzard.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold stockblizzard.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.